What Is an Endectocide and How Do They Work?

An endectocide is a drug that kills both internal parasites (like roundworms and heartworm larvae) and external parasites (like ticks, mites, and lice) with a single dose. The name is a mashup of “endo” (inside) and “ecto” (outside), reflecting this dual action. The most familiar endectocides belong to a chemical family called macrocyclic lactones, which includes ivermectin, moxidectin, and doramectin. They work by locking open certain chloride channels in the nerve and muscle cells of invertebrates, causing irreversible paralysis. Because mammals lack the specific type of channel these drugs target most strongly, and because a protective barrier keeps the drugs out of the mammalian brain, endectocides can wipe out a broad range of parasites at doses that are safe for the host animal or person.

Where Endectocides Came From

The story starts with soil. In the 1970s, the Japanese microbiologist Satoshi Ōmura collected soil samples and cultured new strains of bacteria from the genus Streptomyces, selecting about fifty of the most promising ones to screen for bioactive compounds. One strain, later named Streptomyces avermitilis, came from a golf course in Ito, Japan. The Irish-born parasitologist William Campbell then tested extracts from Ōmura’s strains against animal parasites and found that the compound produced by this particular bacterium had extraordinary potency. He named it avermectin.¹ A chemically modified version of avermectin, ivermectin, went on to become one of the most widely used antiparasitic drugs in both veterinary and human medicine. Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine for this work.²

Ivermectin was the first commercially available endectocide, and it reshaped veterinary parasite control almost overnight. Before its arrival, farmers typically needed one product for worms and a different product for ticks or lice. A single injection of ivermectin handled both. The success of that first compound kicked off an entire drug class, and today there are multiple endectocides on the market with subtly different properties suited to different hosts and situations.

The Drug Family Tree

All commercially important endectocides are macrocyclic lactones, meaning they share a large ring-shaped molecular backbone. Within that family sit two branches. The avermectins, which include ivermectin, abamectin, doramectin, eprinomectin, and selamectin, are fermentation products of Streptomyces avermitilis. The milbemycins, which include moxidectin and milbemycin oxime, come from a related but different soil organism. The key structural difference is that avermectins carry sugar groups attached to one position on the ring, while milbemycins lack those sugars.³ Despite this, both branches share the same basic mechanism, target the same spectrum of parasites, and show the same pattern of toxicity in mammals.⁴

That said, “consanguinity but not identity” is a useful phrase. Moxidectin, for instance, distributes more aggressively into fatty tissues than ivermectin, resists being pumped out of cells by efflux transporters, is metabolized more slowly, and has a longer half-life. The practical result is that effective concentrations persist in the host for longer.⁵ This matters when you are trying to kill parasites that take weeks to mature or when you want extended protection between doses. It also matters for resistance management, as we will see later.

How They Paralyze Parasites

The central target of macrocyclic lactones in nematodes and arthropods is a type of ion channel called the glutamate-gated chloride channel. These channels are found in the nerve and muscle cells of invertebrates, where they help regulate electrical signaling. Ivermectin binds to these channels and forces them open, flooding the cell with chloride ions. The resulting electrical disruption shuts down pharyngeal (feeding) muscle cells and motor neurons. The parasite stops eating, stops moving, and dies.⁶

The binding is essentially irreversible at therapeutic concentrations. Once ivermectin wedges itself into the channel, the channel stays open. There is no recovery for the parasite. This is part of what makes endectocides so potent at relatively low doses: they do not just slow the parasite down, they permanently disable its nervous system.

Why Mammals Are Not Paralyzed Too

Mammals do not have glutamate-gated chloride channels. That is the first and most important layer of safety. Ivermectin can interact with other channel types in mammalian neurons, including GABA receptors and glycine receptors, but those channels sit in the brain, which is protected by the blood-brain barrier. Under normal conditions, ivermectin does not cross this barrier in meaningful amounts, so it never reaches the mammalian channels it could theoretically activate.⁷

A protein called P-glycoprotein acts as the gatekeeper. It sits in the cells lining brain blood vessels and actively pumps drugs like ivermectin back into the bloodstream before they can enter the brain. As long as P-glycoprotein is functional, the drug stays safely outside the central nervous system. This is true even though ivermectin can amplify GABA receptor responses when tested in a dish: at a concentration of about 0.5 micromolar, ivermectin roughly quadrupled the GABA-induced response in mammalian receptors, while moxidectin produced a smaller boost.⁸ The key point is that this interaction only becomes dangerous when the blood-brain barrier fails, either because of a genetic defect, a toxic dose, or certain drug interactions that overwhelm P-glycoprotein.

The MDR1 Mutation in Dogs

This is exactly what happens in certain dog breeds. Collies, Australian Shepherds, and several related herding breeds can carry a four-base-pair deletion in the gene called MDR1 (now often called ABCB1), which codes for P-glycoprotein. Dogs with two copies of this mutation produce no functional P-glycoprotein at all. Without that gatekeeper, macrocyclic lactones freely enter the brain, causing severe neurological toxicity: tremors, blindness, coma, and sometimes death.⁹

The mutation was first confirmed by showing that ivermectin-sensitive Collies were homozygous for the deletion, and that no P-glycoprotein protein could be detected in affected dogs.¹⁰ Genetic testing is now routine and widely recommended before prescribing any macrocyclic lactone to breeds at risk. Dogs that carry only one copy of the mutation generally tolerate standard doses but may still be more sensitive than dogs with no mutation. The takeaway for dog owners: if you have a herding breed, get the genetic test before starting any heartworm or parasite prevention product in this drug class.

What They Kill

The “endo” side of endectocides covers a wide range of internal parasites. Roundworms (nematodes) are the primary targets, and this includes gastrointestinal worms like hookworms, whipworms, and ascarids as well as tissue-dwelling parasites like heartworm larvae. In cattle, a novel combination of the endectocide doramectin with levamisole achieved complete elimination of adult and immature gastrointestinal nematodes in controlled studies.¹¹ In dogs, a combination product containing milbemycin oxime and the insecticide lotilaner showed very high efficacy against larval hookworms and roundworms, and achieved complete prevention of heartworm disease when given monthly.¹²

The “ecto” side covers arthropod parasites. Susceptible external parasites include ticks, lice, mites, and cattle grubs.¹³ That dual action is what makes endectocides so popular on livestock farms. A single injection can protect an animal from both the worms eating it from the inside and the ticks feeding on it from the outside.

Routes of Administration

Endectocides come in injectable, oral, and pour-on formulations, and the choice of delivery route matters more than you might think. The way the drug gets into the body affects how much reaches the bloodstream, how long it lasts, and even how it might accidentally spread to other animals.

Pour-on formulations, where the drug is applied to the skin along the animal’s back, are convenient but come with trade-offs. In horses, pour-on ivermectin produced lower blood levels and slower absorption compared with oral dosing. Binding to the haircoat and skin oils, plus some breakdown in the skin itself, reduced how much drug actually reached circulation.¹⁴ Lower blood levels might sound like a minor concern, but subtherapeutic concentrations are one of the fastest routes to breeding drug-resistant parasites.

Pour-on products also create an unexpected sharing problem. When cattle groom each other by licking, they ingest drug residues from their herd-mates’ coats. Studies have measured oral bioavailability from this “allo-licking” behavior at roughly 14% for doramectin, 18% for ivermectin, and 26% for moxidectin.¹⁵ That means untreated animals in the same pasture may absorb low, uncontrolled amounts of drug through social grooming, again creating conditions that favor resistance development. In goats, the drug’s behavior in the body is further influenced by the animal’s nutritional state, fat reserves, and parasite burden.¹⁶

The Resistance Problem

Parasites are evolving resistance to macrocyclic lactones, and in some livestock systems it has become a serious economic threat. One of the most studied resistant parasites is Haemonchus contortus, a blood-feeding stomach worm of sheep and goats that can cause fatal anemia. Research into how this worm resists endectocides has pointed to a family of proteins called P-glycoproteins, essentially the worm’s own version of the pump that protects the mammalian brain. Resistant worms crank up production of these pumps, shoving the drug out of their cells before it can reach the chloride channels. Work in the model organism C. elegans showed that multiple P-glycoprotein genes are involved, with PGP-6 playing a particularly important role.¹⁷

The involvement of P-glycoproteins has inspired a logical countermeasure: combine the endectocide with a P-glycoprotein inhibitor to disable the worm’s efflux pump. Early experiments used verapamil, a calcium-channel blocker already available for human heart conditions, and a research compound called CL 347,099. When either blocker was combined with ivermectin or moxidectin, worm counts in resistant strains dropped significantly compared with the endectocide alone.¹⁸ More recent work has tested third-generation P-glycoprotein inhibitors like tariquidar and zosuquidar, which are more selective and potent. These boosted ivermectin sensitivity in resistant H. contortus larvae by up to six-fold in migration assays.¹⁹ None of these combinations are commercially available for livestock yet, but they represent one of the more promising strategies being explored.

Endectocides in Human Medicine

Ivermectin is not just an animal drug. It has been a cornerstone of mass drug administration campaigns against river blindness (onchocerciasis) and lymphatic filariasis for decades.²⁰ In those programs, entire communities take a single oral dose once or twice a year, targeting the microfilariae (larval-stage worms) that cause the most damage. The drug does not kill the adult worms outright but suppresses their offspring long enough to interrupt transmission.

A more recent and more speculative application involves malaria. Mosquitoes that bite a person who has recently taken ivermectin ingest the drug in the blood meal, and the effect can be lethal. Laboratory studies have shown that ivermectin concentrations in the range of 10 to 100 nanograms per milliliter significantly reduce survival in Anopheles mosquitoes over a two-week window. To cut a mosquito population in half within seven days, concentrations need to stay above roughly 20 nanograms per milliliter.²¹ The idea is that mass drug administration for filariasis could double as a supplemental malaria control tool. Randomized trials are exploring whether giving ivermectin in single or multi-day doses can reduce malaria transmission during campaigns, because each mosquito that feeds on a treated person has a lower probability of surviving long enough to transmit the parasite.²² This is still investigational, but the concept of turning a treated human population into a weapon against the vector is genuinely novel.

Environmental Fallout

The potency that makes endectocides so useful inside the host creates problems outside it. Macrocyclic lactones are excreted largely unchanged in feces, and livestock dung laced with drug residues is toxic to the invertebrate communities that break it down. A field study found that conventional ivermectin use in cattle reduced dung beetle species richness, abundance, and biomass. Beetles relocated less dung, and dung accumulated on the pasture surface over time, altering soil structure and nutrient cycling.²³

Not all dung-dwelling organisms are equally vulnerable. A controlled study in Spain found that dung fly larvae were the most sensitive group, with significant population declines even at the lowest tested concentrations. Dung beetles showed mixed results, with one species declining sharply while another was barely affected at the same dose. Mites and springtails were not harmed. But overall, dung from treated cattle broke down more slowly than dung from untreated cattle, confirming that even when some species survive, the loss of the most sensitive decomposers is enough to slow the whole process.²⁴ This has pushed some farmers toward more targeted dosing strategies, treating only the most heavily parasitized animals rather than whole herds, or timing treatments to avoid peak beetle breeding seasons.

Residues in Meat and Milk

Because endectocides persist in fatty tissue and are excreted slowly, regulatory agencies set maximum residue limits and enforce withdrawal periods before treated animals can be slaughtered for food. In the European Union, the maximum residue limits for ivermectin are 100 micrograms per kilogram in fat and liver and 30 micrograms per kilogram in kidney. After a subcutaneous injection, withdrawal periods are 49 days for ivermectin alone and 66 days when combined with clorsulon, a fluke treatment. The highest residue concentrations turn up in fat, liver, and the tissue around the injection site.²⁵

Milk is a particular concern. Ivermectin is not licensed for use in dairy animals producing milk for human consumption in most regulatory frameworks, precisely because the drug persists in milk and milk-derived products for an extended period. Off-label use does occur, especially in smallholder farming systems, and monitoring programs exist to catch violations. For consumers, the practical risk from properly regulated meat and dairy is very low, but these residue rules are a good example of the hidden complexity behind a drug that seems straightforward at the farm level.